Abstract: The actions of tumor promoters on the coupling of muscarinic receptors to the hydrolysis of inositol lipids and the generation of Ca2+ signals were examined in the human neuroblastoma SH-SY5Y cell line. Pretreatment of SH-SY5Y cells with 50 nM 12-0-tetradecanoylphorbol 13-acetate (TPA) for 5 days resulted in neuronal differentiation, a 28% decrease in both N-[3H]methylscopolamine and [3H]-scopolamine binding, and a significantly larger reduction (48%) in agonist-stimulated 3H-inositol phosphate generation. Whereas mezerein could mimic the effects produced by TPA, the biologically inactive 4a-phorbol 12,13-didecanoate was without effect on both antagonist binding and agonist-stimulated phosphoinositide (PPI) turnover. A decline (-50%) in the agonist-mediated rise in cytoplasmic Ca2+ and a substantial loss of protein kinase C activity also were observed following pretreatment with TPA or mezerein. The ability of fluoride, an agent capable of direct activation of guanine nucleotide binding proteins, to stimulate 3FI-inositol phosphate release was significantly reduced in SH-SYSY cells treated with these agents. Furthermore, pretreatment of SH-SYSY neuroblastoma cells with TPA or mezerein impaired 3H-inositol phosphate formation induced by the addition of either guanosine 5'-0-( 3-thiotriphosphate) or carbamylcholine to digitonin-permeabilized cells, but not that elicited by the addition of 2 mM CaC12. Although cells cultured in the presence of serum-free media also exhibited neuronal differentiation, no significant alteration in either muscarinic receptor number or agonist-stimulated PPI hydrolysis was observed. The results suggest that TPA and mezerein decrease agonist-stimulated PPI hydrolysis and Ca2' signaling in SH-SYSY cells not only by a reduction in muscarinic receptor number but also through an inhibition ofguanine nucleotidestimulated PPI turnover. Key Words: PhosphoinositidcHuman neuroblastoma-SH-SYSY-Muscarinic receptorMezerein-12-0-Tetradecanoylphorbol 13-acetate. Cioffi C. L. and Fisher S. K. Reduction of muscarinic receptor density and of guanine nucleotide-stimulated phosphoinositide hydrolysis in human SH-SY5Y neuroblastoma cells following long-term treatment with 12-0-tetradecanoylphorbol 13-acetate or mezerein. J. Neurochem. 54, 1725-
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Human neural tumor cells, such as the SH-SY5Y neuroblastorna clone, can differentiate morphologically upon prolonged exposure to low concentrations of the biologically active phorbol ester, I 2-0-tetradecanoylphorbol 13-acetate (TPA), an activator of protein kinase C (PKC) (Akerman et al., 1984; Nishizuka, 1984; Adem et al., 1987; Heikkila et al., 1987) . This neuronal differentiation is associated with neurite outgrowth (Pahlman et al., 198 1, 1984) , electrical excitability (Akerman et al., 1984) , increases in neurotransmitter levels, and neurosecretory granules (Pahlman et al., 198 1) . Although the effects of phorbol esters on difler-I726 C. L. CIOFFI AND S. K. FISHER entiation have been well documented, little is known of possible alterations in signal transduction mechanisms under these conditions. SH-SYSY neuroblastoma cells express muscarinic acetylcholine receptors (Adem et al., 1987; Serra et al., 1988; Lambert et al., 1989) , which are coupled to breakdown of inositol lipids (Serra et al., 1988; Fowler et al., 1989) . Previous reports have demonstrated that chronic TPA treatment induces a down-regulation of muscarinic receptor number in this neuronal clone (Adem et al., 1987; Heikkila et al., 1987) . In the present study, we have utilized SH-SYSY cells to examine the coupling of muscarinic receptors to the hydrolysis of inositol lipids and Ca2+ signaling following differentiation by means of either TPA or mezerein, or, alternatively, by deprivation of fetal calf serum. The results indicate that whereas long-term treatment of SH-SYSY cells with either TPA or mezerein elicits a reduction in muscarink receptor number, an even more pronounced inhibition of agonist-stimulated inositol phosphate generation and of Ca2+ mobilization occurs. Furthermore, using either intact cells stimulated with fluoride or digitonin-permeabilized cells stimulated with guanosine 5'-0-(3-thiotriphosphate) (GTPyS), we demonstrate that the effects of TPA and mezerein on inositol lipid turnover result not only from a loss of muscarinic receptors, but also from an inhibition of the guanine nucleotide binding protein (G,) that regulates phosphoinositide (PPI) hydrolysis in these cells. In contrast with the effects observed for tumor promoters, no significant changes in either muscarinic receptor density or agonist-stimulated PPI hydrolysis occurred when differentiation was induced by culturing SH-SYSY cells in serum-free media. 
MATERIALS AND METHODS

Cell culture conditions
Human SH-SY5Y neuroblastoma cells (passage 65-80) were grown in tissue culture flasks (75 cm2/250 ml) in 20 ml of DMEM with high glucose supplemented with 10% (vol/ vol) FBS. The cells were incubated at 37°C in an atmosphere consisting of 10% COz and 90% humidified air. Confluent cells grown for 10-20 days were subcultured by incubation in a modified Puck's D, solution (Honegger and Richelson, 1976) . The cells were collected by centrifugation (300 g for 1 min), resuspended into DMEM, and redistributed into culture flasks. The culture medium was changed on day 5 and on alternate days thereafter by the addition of 10 nil of fresh DMEM and removal of 10 ml of medium.
Differentiation
Confluent cells were subcultured in tissue culture flasks (75 cm2/250 ml) in DMEM with 10% FBS in the absence or presence of TPA (50 M) or mezerein (100 nM). Stock solutions were prepared in absolute ethanol and were always introduced to newly passaged cells; the same ethanol concentration was present in the control cells. All experiments were performed with 80-90% confluent cultures on day 5 following subculture. For differentiation in the absence of fetal calf serum, cells were grown in the presence of DMEM alone for 6-7 days. Intact cells were harvested for assay as described above. The cell pellet was resuspendcd in HEPES physiological salt buffer solution (142 mM NaCI, 5.6 mM KCI, 2.2 mM CaCI2, 3.6 mA4 NaHC03, 1 mM MgC12, 5.6 m M D-glucose, and 30 mM Na' HEPES; pH 7.4).
Electrophoresis of labeled muscarinic receptors
Intact SH-SY5Y cells were labeled with [3H]PBCM, analyzed by sodium dodecyl sulfate-urea gel electrophoresis and visualized autoradiographically as described previously (Fisher and Heacock, 1988) .
Radioligand binding assays
The binding of [3H]NMS and [3H]scopolamine to muscarinic receptors on intact SH-SY 5Y cells was measured as previously described (Fisher, 1988) .
Assay for release of labeled inositol phosphates
Intact cells. SH-SYSY cells were harvested as described above, resuspended in HEPES buffer containing [3H]inositol (-10 gCi/ml) at a protein concentration of 1 mg/ml, and allowed to prelabel for 60 min at 37°C. After 55 min, lithium chloride was added to achieve a final concentration of 10 mM. The reaction was initiated by the addition of 50 p1 of carbamylcholine or buffer to assay tubes containing 45O-pl aliquots of labeled cells followed by a 60-min incubation at 37°C. When fluoride was used as an activator, intact cells were allowed to prelabel overnight with 5 pCi/ml [3H]inositol. A 50-pl aliquot of NaF was added to assay tubes containing 450 p1 of labeled cells and incubated for 20 min at 37°C. (A 20-min incubation was chosen due to the lack of linearity of NaF-stimulated 3H-inositol phosphate formation with further incubation.) The reaction was terminated by addition of 1.5 ml of chloroform/methanol(1:2, vol/vol), and the total water soluble inositol phosphate fraction was scparated and quantitated by ion-exchange chromatography . The majority of the radiolabel recovered was in inositol monophosphate (63%), with the remainder in
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glycerophosphorylinositol (34%), inositol bisphosphate (2.3%), inositol trisphosphate (0.4%), and inositol tetrakisphosphate (0.3%). The ratios of 3H-inositol phosphates remained unchanged following TPA treatment. Basal levels of 3H-inositol phosphate release were subtracted from all carbamylcholine-and NaF-stimulated values. In all experiments, a 200-p1 aliquot was removed from the organic phase to determine the incorporation of [3H]inositol into the phospholipid fraction (Fisher and Bartus, 1985) .
Permeabilized cells. The release of inositol phosphates from digitonin-permeabilized cells was measured as described previously (Fisher et al., 1989) .
Measurement of cytoplasmic calcium concentration
Cytoplasmic Ca" concentrations ([Ca*+]J were determined by the use of the fluorescent Ca2+ indicator, fura-2, as previously described (Fisher et al., 1989) . Single-wavelength fluorescence was routinely monitored using a Shimadzu RF-5000 spectrofluorophotometer. In some experiments, [Ca2+Ii in fura-2/AM-loaded cells was determined by the dual-wavelength method of Grynkiewicz et al. (1985) by manual switching of the excitation wavelengths. Both methods yielded similar results.
PKC assay
Intact SH-SY5Y cells were harvested as described above and homogenized at 4°C in three volumes of homogenization buffer (20 mMTris-HC1, pH 7.5, I mMEGTA, 1 mMEDTA, 2 mM dithiothreitol, 250 m M sucrose) plus 1 mM phenylmethylsulfonyl fluoride, 50 pg/ml leupeptin, and 1 pg/ml pepstatin A using a Brinkmann Polytron (setting 7, three 5-s bursts). The homogenate was centrifuged at 100,000 g for 60 min at 4°C. The resultant supernatant fluid was collected and is referred to as the cytosolic fraction. To solubilize any PKC activity tightly associated with the membrane, the membrane pellet was resuspended in Tris homogenization buffer containing 0.1% Triton X-100 and extracted on ice for 45 min. Following centrifugation at 100,000 g for 60 min at 4"C, the supernatant fluid was collected to obtain the membrane fraction. The resultant cytosolic and membrane fractions were loaded onto DEAE-Sephacel columns (I-ml bed volume) previously equilibrated with homogenization buffer. The columns were washed with five volumes of the same buffer, and PKC was eluted with 100 mM NaCl in homogenization buffer. PKC activity was determined by measuring the transfer of 32P from [y3'P]ATP to histone.
The standard reaction mixture contained 20 mM Tris-HC1 (pH 7 4 , 5 mM magnesium acetate, 45 pM CaCl,, 200 pg histone III-S/ml, 250 pM [y-32P]ATP, 160 pg phosphatidylserine/ml, 1.6 pg diolein/ml, and the enzyme solution to be assayed in a final volume of 250 pl. Phosphatidylserine and diolein were dried from chloroform and sonicated in 20 mM Tris-HCI (pH 7.5). The reactions were performed in plastic tubes and were initiated by the addition of 30 and 50 pl of the cytosol and membrane fractions, respectively. After 5 min at 3 0 T , the assay was terminated by the addition of 3 ml of 25% trichloroacetic acid (TCA) and filtered over a Millipore filter (0.45 pm). The tubes were washed three times with 25% TCA and the contents added to the filter; two further TCA washes of the filter followed. PKC activity was computed according to the following equation:
where A = the amount of 32P incorporation into histone in the presence of tissue extract, Ca'+, phosphatidylserine, and diolein; B = the amount of 32P incorporation into histone in the presence of Ca2+ and tissue extract; and C = the amount of 32P incorporation into histone in the presence of 20 mM EGTA and tissue extract (no Ca", phosphatidylserine, or diolein).
Background activity was determined in samples in which tissue, phosphatidylserine, diolein, and Ca2+ were omitted and an additional 20 mM EG'TA added.
Data analysis
Results are expressed as mean f SEM values. Student's t tests (paired or unpaired) were used to determine statistical significance. Proteins were measured according to the method of Geiger and Bessman (1972) , except for the PKC assay, where interference from assay reagents necessitated the use of Bio-Rad Protein Assay. Apparent Ki values for radioligand binding studies were calculated from the Cheng and Prusoff equation (1973) . Competition curves were analyzed by the LIGAND program (Munson and Rodbard, 1980) . Saturation isotherms were analyzed according to the Scatchard transformation ( 1949).
RESIJLTS
Characterization of muscarinic acetylcholine receptors on SH-SYSY cells
Because some uncertainty exists regarding the pharmacological identity of the muscarink receptors present on SH-SYSY cells (Adem et al., 1987; Serra et al., 1988; Lambert et al., 1989) , our initial studies were directed toward a pharmacological and biochemical characterization of the receptor subtype expressed in the cell line used during the course of the present study. 2) . The K, value obtained for pirenzepine displacement was 700 k 100 &(n = 3), indicating the presence of a class of muscarinic receptors with low affinity for the antagonist, in agreement with the results of Lambert et al. (1989) . Although the Hill coefficients (0.89 k 0.03; Fig. 2 ) were significantly less than 1.0 ( p < 0.05), the data could only be successfully fit by LIGAND according to a one-site model. However, a small number of high-affinity pirenzepine binding sites has been detected in two previous reports using this clone (Adem et al., 1987; Serra et al., 1988) . SH-SYSY cells are a subclone of the parent SK-N-SH neural cell line (Biedler et al., 1978) , which has been found to exhibit an M3 muscarink subtype that couples to PPI turnover (Fisher and Heacock, 1988 [3H]PBCM and the labeled peptides analyzed by sodium dodecyl sulfate-urea gel electrophoresis. A major labeled species of M, 98,000 was detected, as previously observed for the parent SK-N-SH cell line ( Fig. 3 ; Fisher and Heacock, 1988) . Taken together, these findings suggest that the SH-SY5Y cell line used in the present study contains a high density of high molecular weight muscarinic receptors of the M3 (pirenzepine low-affinity) subtype, and are in agreement with the pharmacological data recently presented by Lambert et al. ( I 989) for the parent SK-N-SH cell line (Fisher and Heacock, 1988) .
Changes in cell morphology of SH-SY5Y cells treated with either TPA or mezerein or cultured in the absence of fetal calf serum SH-SYSY cells, cultured for up to 5 days in the presence of 50 nA4 TPA, expressed long, neuritic processes indicative of neuronal differentiation, as previously described (Pahlman et al., 1981 (Pahlman et al., , 1984 Adem et al., 1987; Heikkila et al., 1987) . Identical morphological changes were induced by treatment with 100 nA4 mezerein. When SH-SYSY cells were cultured for up to 7 days in media devoid of fetal calf serum, morphologically differentiated cells also resulted. Although these cells had long, straight processes, the appearance of many cell clusters and greater distances between cells made them morphologically distinct from cells treated with TPA or mezerein. (Fig. 4) . Under similar conditions, there was also a time-dependent, albeit larger, inhibition of muscarinic receptor-stimulated accumulation of 3H-inositol phosphates (Fig. 4) . Acute exposure of SH-SY5Y cells to 50 I&' TPA for either 15 min or 18 h had little or no effect on specific . )
Changes in muscarinic receptor
was measured as described in Materials and Methods using 10 mM carbamylcholine. Data are expressed relative to control cells, which were not pretreated with TPA, and are presented as the mean of three to four independent experiments.
[3H]NMS binding (>94% of control) or agonist-stimulated PPI hydrolysis (>95% of control). To further characterize the TPA-induced diminution of muscarinic receptor density and of 3H-inositol phosphate generation, all subsequent experiments were performed with a standard 5-day, 50-nM TPA pretreatment period.
Scatchard analysis of [3H]NMS binding in untreated cells revealed a B,,, of 345 f 29 fmol/mg of protein (n = 4), with a corresponding KD value of 0.82 * 0.09 nM (Fig. 5) KD values of 252 f 36 fmol/mg of protein and 0.83 f 0.09 nM, respectively (Fig. 5) . Similarly, when [3H]scopolamine was utilized as the radioligand, a 27% reduction in B, , , with no change in K D , was observed following TPA treatment (data not shown).
To determine whether the inhibition of muscarinic receptor-mediated hydrolysis of inositol lipids was a result of a decrement in the maximal response and/or a change in agonist potency, we examined the ability of increasing concentrations of carbamylcholine to generate 3H-inositol phosphates in untreated and TPAtreated cells. The results demonstrate that TPA pretreatment reduces the extent of agonist-stimulated inositol phosphate release by decreasing the maximal response without changing the ECS0 value (Fig. 6) . Basal 3H-inositol phosphate release was unaffected by prior treatment of SH-SY5Y cells with TPA.
Muscarinic receptor density and stimulated PPI hydrolysis in SH-SYSY cells grown in serum-free media
To determine whether differentiation of SH-SY5Y cells invariably leads to alterations in muscarinic receptor signal transduction events, differentiation also was induced by removal of fetal calf serum from the medium. A small, although not significant 
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necessarily accompanied by changes in muscarinic receptor-effector coupling.
Comparison of the effects of phorbol esters and mezerein on muscarinic receptor number and stimulated PPI hydrolysis It was consistently noted that TPA produced a greater reduction in carbamylcholine-stimulated 3H-inositol phosphate generation than in muscarinic receptor density, whereas the biologically inactive 4a-PDD was without effect on both of these parameters (Table 1) . On the other hand, mezerein was able to mimic the effects produced by TPA and elicited a 26 and 53% inhibition of specific [3H]NMS binding and 3H-inositol phosphate generation, respectively (Table  1) . Neither TPA nor mezerein pretreatment influenced the incorporation of myo-[3H]inositol into the inositol lipid pool under basal (no agonist) conditions [98 f 6% (n = 6) and 104 k 8% (n = 4) of control for TPA and mezerein, respectively]. When SH-SYSY cells were cultured in the presence of both TPA and mezerein, less than additive effects resulted (data not shown). Thus, these agents appear to mediatc their effects through a similar pathway or mechanism.
Changes in [Ca2+ji in SH-SYSY cells following treatment with TPA or mezerein
The fluorescent indicator, fura-2, was utilized to monitor both basal and agonist-stimulated [Ca"], values in human neuroblastoma cells. Under resting conditions, a basal [Ca"], value of 39 f 4 nM (n = 13) was obtained in untreated SH-SYSY cells. Upon agonist addition, a rapid rise of [Ca"], to a value of 350 f 24 nM(n = 13) was observed (Fig. 7A ). This increase was transient and was followed by a decline to a plateau phase of the [Ca2'li signal ( Fig. 7A ; see Fisher et al., 1989) . Subsequent addition of atropine reduced the plateau Ca2+ value to that of basal [Ca2'], (Fig. 7A) . Pretreatment of SH-SYSY cells with TPA or mezerein depletes total PKC activity Chronic exposure of cells to phorbol esters has been reported to induce the down-regulation of PKC activity. To determine the effects of long-term treatment with TPA and mezerein on levels of PKC, the activity of this enzyme was measured in both cytosol and membrane fractions obtained from SH-SYSY cells treated for 5 days with these agents. In untreated cells, 70% of total PKC activity was associated with the cytosolic fraction, with the remainder localized to the
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membrane (Table 2) . A decrease in the amount of total PKC activity was apparent after treatment with 50 I 1 M TPA for 5 days, with levels of the enzyme reaching only 16% of control (Table 2) . Pretreatment with 100 nM mezerein also led to a similar depletion of PKC activity ( Table 2) .
TPA and mezerein treatments inhibit NaF-and GTPyS-stimulated inositol phosphate production Because the loss of muscarinic receptors could not fully account for the decrement observed in stimulated PPI hydrolysis, we investigated the possibility that TPA and mezerein were inhibiting inositol phosphate generation at an additional site distal to the receptor. Intact SH-SY 5Y cells were prelabeled for 24 h and then challenged with NaF, a compound capable of stimulating the accumulation of inositol phosphates via direct interaction with G,. Table 3 shows that prior treatment of human neuroblastoma cells with TPA or mezerein significantly impaired the ability of NaF to induce 3H-inositol phosphate generation when compared with untreated cells. Under these conditions, carbamylcholine-stimulated 3H-inositol phosphate formation was reduced to the same extent as that reported using the acute labeling paradigm (Tables 1 and 3) .
The site of TPA-and mezerein-induced inhibition of PPI hydrolysis was investigated further utilizing digitonin-permeabilized cells stimulated with GTPyS, a nonhydrolyzable analog of GTP. Addition of either GTPyS or carbamylcholine led to an increase in 3H-inositol phosphate generation in untreated cells, whereas a combination of both agents resulted in a synergistic accumulation (Fig. 8) . Inclusion of 3 mM guanosine 5'-0-(2-thiodiphosphate) (GDPPS) substantially (40-70%) reduced carbamylcholine-stimulated and carbamylcholine plus GTPyS-stimulated 3H-inositol phosphate release from permeabilized cells. Furthermore, inclusion of 20 pM atropine attenuated stimulated PPI turnover observed in the presence of Intact SH-SY5Y cells were pretreated with the designated agents for 5 days. Homogenates were prepared and PKC activity (phosphatidylserine + diolein-induced 32P phosphorylation of histone 111-S) was determined in cytosolic and membrane fractions as described in Materials and Methods. Data are the average from two independent experiments, which differed by <10%. Intact SH-SY5Y cells were treated with or without 50 nM TPA or 100 nA4 mezerein for 5 days and prelabeled with rny~-[~H]inositol (5 pCi/ml) for the last day of this treatment. Intact, prelabeled cells (-500 jtg of protein) were incubated with 30 m/ M NaF or 10 mM carbamylcholine for 20 min at 37°C. Results represent the means from four independent experiments. In pretreated cells, 3H-inositol phosphate release in basal and i n fluoride-and carbamylcholinestimulated incubations were 1,277 f 334, 3,790 & 610, and 22,962 k 4,033 dpm/mg of protein, respectively. In untreated cells, a combination of fluoride and carbamylcholine resulted in accumulation of 3H-inositol phosphate generation greater than that observed with fluoride alone, but less than the maximal stimulation noted in the presence of agonist alone. carbamylcholine plus GTPyS to the level obtained for GTPyS alone, as previously observed for the SK-N-SH cell line (Fisher et al., 1989) . The ability of carbamylcholine to increase 3H-inositol phosphate release was reduced in TPA-and mezerein-treated SH-SY5Y cells to about 30% of control values (Fig. 8) . GTPySstimulated 3H-inositol phosphate release was decreased to 7 1 and 66% of control in cells treated with TPA and mezerein, respectively. Although a combination of carbamylcholine and GTPyS still elicited a synergistic effect in permeabilized cells obtained from both treated groups, the maximal stimulation was reduced to 70% when compared with untreated cells. Basal release of 3H-inositol phosphates was not appreciably altered in treated cells. Direct activation of phospholipase C activity by the addition of 2 mM CaC12 to digitonin-permeabilized cells resulted in a five-to sevenfold increase in 3H-inositol phosphate release over basal levels. This ability of Ca2+ to activate the enzyme directly was not impaired in cells pretreated with either TPA or mezerein for 5 days (88-102% of control, n = 2). Taken together, the results suggest that treatments with TPA and mezerein inhibit not only muscarinic agonist-induced 3H-inositol phosphate formation but also that resulting from direct activation of G,.
DISCUSSION
The principal conclusion to emerge from the present study is that although long-term treatment of human neuroblastoma SH-SY5Y cells with TPA or mezerein results in a loss of muscarinic receptor number, a more pronounced reduction is observed for two biochemical consequences of receptor activation, namely agoniststimulated PPI hydrolysis and Ca2+ signaling. Evidence obtained from both intact and permeabilized cells indicates that an additional site of action of these tumor promoters, at the level of G,-stimulated PPI hydrolysis, may account for their marked inhibitory effects on inositol lipid signaling events.
In agreement with previous reports (Adem et al., 1987; Heikkila et al., 1987) , chronic treatment of SH-SYSY cells with TPA resulted in a loss of muscarinic receptor binding sites, reaching a maximal steady state after 5 days of treatment (Fig. 4 and Table I ). Comparable losses of both ['H]scopolamine and [3H]NMS binding indicate that both cell surface and sequestered muscarinic receptors are equally down-regulated following chronic TPA treatment (Fig. 4) . Acute exposure of intact, confluent SH-SYSY cells with 50 nM TPA did not alter muscarinic receptor density. In contrast, a loss of muscarinic receptors has been reported for other cell lines following acute exposure to a similar concentration of TPA (Liles et al., 1986; Pearce et al., 1988) .
Although muscarinic receptor density was reduced following chronic TPA and mezerein treatment, a consistently larger attenuation of agonist-induced PPI hydrolysis was observed (Table 1) . This effect is due to a decreased maximal response without a change in the potency of the agonist for the receptor (Fig. 6) . Utilizing intact and digitonin-permeabilized SH-SYSY cells, we obtained evidence that TPA and mezerein induce additional inhibitory effects on PPI hydrolysis at a site distal to the receptor. Pretreatment of cells with TPA or mezerein significantly reduced the ability of fluoride, an agent that causes activation of Gp through its dissociation, to stimulate PPI hydrolysis (Table 3) . Similarly, the ability of GTPyS to enhance inositol phosphate release from digitonin-permeabilized cells also was diminished following pretreatment with these agents (Fig. 8) . TPA and mezerein did not affect the basal incorporation of myo-['H]inositol into the inositol lipid pool, suggesting that substrate depletion probably does not account for the TPA-and mezereininduced reduction in PPI hydrolysis. Thus, the present results are consistent with the possibility that in SH-SY5Y cells, treatment with either tumor promoter results in inhibition of stimulated PPI hydrolysis at a site either at or distal to G,. Although inhibition of receptor-stimulated PPI hydrolysis following acute exposure of tissues to relatively high concentrations of phorbol esters is well documented (see Snider et al., 1987 and references therein), the underlying mechanism remains uncertain. In this context, inhibition of the G protein interaction with phospholipase C following acute TPA treatment has been demonstrated previously for 132 1 N 1 human astrocytoma cells (Orellana et al., 1987) and HL60 cells (Cockcrofi and Stutchfield, 1988; Geny et al., 1989) , but not for primary astrocyte cultures (Pearce et al., 1988) . Thus, the mechanism of TPA-induced inhibition of stimulated PPI hydrolysis may be tissue-specific.
Pretreatment of SH-SYSY cells with TPA or mezerein also resulted in a reduction in the carbamylcholinestimulated rise in [Ca"], to an extent similar to that observed for stimulated PPI hydrolysis (-50%). In contrast, no effect of the tumor promoters on basal [Ca2'], was observed. These results indicate that the magnitude of the rise in [Ca2+] , is proportional to the extent of PPI hydrolysis and suggest that these two events are closely coupled in SH-SY5Y cells, as previously noted for SK-N-SH neuroblastoma cells (Fisher et al., 1989) .
In the SH-SYSY neuronal cell line, mezerein elicited morphological and biochemical changes similar to those induced by TPA ( Table I ), suggesting that these two agents function through a similar pathway or mechanism. Despite the fact that mezerein does not contain a diacylglycerol-like molecule in its structure, the compound is capable of activating PKC both in vitro and in vivo in a manner analogous to TPA (Miyake et al., 1984) . In our study, long-term exposure to TPA or mezerein led to a marked depletion of total PKC activity in SH-SY5Y cells (Table 2) . These results are consistent with the occurrence of down-regulation of PKC activity upon chronic exposure to phorbol esters, as observed for other cultured cell lines (Ballester and Rosen, 1985; Blackshear et al., 1985; Hepler et al., 1988) . Conversely, 4a-PDD, which does not activate PKC, did not reduce either specific ['HINMS binding or stimulated PPI hydrolysis (Table l) , providing further evidence that activation of PKC is involved, at least in part, in the long-term effects of biologically active tumor promoters. Inhibition of guanine nucleotide-stimulated PPI hydrolysis in SH-SYSY cells following TPA or mezerein treatment may reflect PKC-
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mediated phosphorylation of G,, as previously proposed to occur in 132 1Nl astrocytoma cells (Orellana et al., 1987) . TPA treatment of platelets results in the PKC-induced phosphorylation of the inhibitory guanine nucleotide regulatory protein Gi (Katada et al., 1985) . Alternatively, PKC may directly phosphorylate phospholipase C itself (Rhee et al., 1989) . However, this possibility appears less likely in SH-SYSY cells as basal 3H-inositol phosphate release was unaffected by pretreatment with either TPA or mezerein. Moreover, the ability of a high concentration of calcium to activate phospholipase C directly and stimulate 3H-inositol phosphate release from digitonin-permeabilized SH-SYSY cells remained unchanged following chronic TPA or mezerein treatment, thus further reducing the likelihood of an inhibitory effect of the tumor promoters on phospholipase C itself.
Whereas morphological differentiation of SH-SYSY cells resulted from pretreatment with TPA or mezerein, or removal of fetal calf serum, alterations in receptor number and in stimulated PPI turnover were observed only following pretreatment of the cells with the tumor promoters. These results suggest that differentiation of SH-SYSY cells is not necessarily accompanied by changes in signal transduction events, and that the inhibitory effects of TPA and mezerein are likely to result from the direct activation of PKC and/or its subsequent down-regulation.
In summary, long-term exposure to TPA or mezerein resulted in a decline in muscarinic receptor-mediated PPI hydrolysis with a concomitant decrease in agonist-induced Ca2+ mobilization and PKC activity in human neuroblastoma SH-SYSY cells. Our results indicate that the inhibitory effects produced by these agents are a consequence of a reduction in muscarinic receptor number as well as inhibition of G,-stimulated PPI hydrolysis.
